Hepatitis C-Clinical trials

Treatment Action Group publishes Guide to Clinical Trials for People With Hepatitis C

There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you.

Click Here For Clinical Connections; International Search

Center for Drug Evaluation and Research: www.fda.gov/cder

CenterWatch Web site: www.centerwatch.com

NIH Clinical Trials Web site: www.clinicaltrials.gov

Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed St

Conditions: Chronic Hepatitis C9 Locations available

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C V

Conditions: Hepatitis C, Chronic8 Locations available

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Conditions: Hepatitis C, Chronic10 Locations available

HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

Conditions: HIV Infection - Hepatitis C1 Location available

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/HCV Negative Volunteers

Conditions: Hepatitis C - HIV1 Location available

TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Conditions: Hepatitis C2 Locations available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (R

Conditions: Chronic Hepatitis C, Hepatitis C, Hepatitis C Virus (HCV)10 Locations available

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Conditions: Hepatitis C1 Location available

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Conditions: Hepatitis C - Liver Transplantation7 Locations available

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients , And With Cope

Conditions: Hepatitis C, Chronic2 Locations available

TMC435HPC3007 - Phase III Trial of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Conditions: Hepatitis C1 Location available

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Conditions: Hepatitis C25 Locations available

A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM4)

Conditions: Hepatitis C, Chronic2 Locations available

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Conditions: Hepatitis C Virus14 Locations available

TMC435-TiDP16-C216 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Conditions: Hepatitis C3 Locations available

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Conditions: Hepatitis C, Chronic2 Locations available

BMS-790052 Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Conditions: Hepatitis C3 Locations available

Study of Safety & Efficacy of INX-08189 in Adjunctive Treatment With Pegasys® Copegus® in Chronically-infected HCV Genotype 2 and 3

Conditions: Hepatitis C5 Locations available

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Conditions: Hepatitis C, Chronic4 Locations available

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Conditions: Hepatitis C11 Locations available

Safety Study of Regimens of PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Infection

Conditions: Hepatitis C, Chronic3 Locations available

Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients

Conditions: Hepatitis C6 Locations available

Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects

Conditions: Hepatitis C10 Locations available

BI 201335 Used in Treatment Naive Patients Infected With Genotype 1 Chronic Hepatitis C Infection

Conditions: Hepatitis C69 Locations available

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Conditions: Hepatitis C Virus (HCV), Chronic Hepatitis C8 Locations available

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Pa

Conditions: Hepatitis C10 Locations available

MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)

Conditions: Hepatitis C, Chronic25 Locations available

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype

Conditions: Hepatitis C, Chronic2 Locations available

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks

Conditions: Hepatitis C, Chronic14 Locations available

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Conditions: Hepatitis C1 Location available

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV)

Conditions: Chronic Genotype 1a or 1b HCV Infection2 Locations available

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Conditions: Hepatitis C Infection3 Locations available

Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders

Conditions: Hepatitis C Chronic8 Locations available

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Conditions: Hepatitis C, Chronic19 Locations available

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC

Conditions: Chronic Hepatitis C7 Locations available

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b HCV Infection

Conditions: Hepatitis C, Chronic2 Locations available

See All Trials Here